<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Insulin resistance: Definition and clinical spectrum</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Insulin resistance: Definition and clinical spectrum</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Insulin resistance: Definition and clinical spectrum</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christos Mantzoros, MD, DSc</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Nathan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 14, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Insulin resistance can be broadly defined as a subnormal biological response to normal insulin concentrations. By this definition, it may pertain to many biological actions of insulin in many tissues of the body. Typically, however, in clinical practice, insulin resistance refers to a state in which a given concentration of insulin is associated with a subnormal glucose response [<a href="#rid1">1</a>].</p><p>The term first came into use several years after the introduction of insulin therapy in 1922 to describe occasional diabetic patients who required increasingly large doses of insulin to control hyperglycemia. Most of these patients developed insulin resistance secondary to antibodies directed against the therapeutic insulin, which at that time was both impure and derived from nonhuman species [<a href="#rid2">2</a>]. Anti-insulin antibodies in titers sufficient to impair insulin action are rare in patients treated with recombinant human insulin, and the broad spectrum of clinical disorders in which insulin resistance plays a major role has changed markedly  (<a class="graphic graphic_table graphicRef75383" href="/d/graphic/75383.html" rel="external">table 1</a>).</p><p>This topic will review the definition, clinical features, and diagnosis of insulin resistance. Possible mechanisms for the development of insulin resistance are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1810.html" rel="external">"Pathogenesis of type 2 diabetes mellitus"</a>.)</p><p>The definition, prevalence, clinical implications, and therapy of the metabolic syndrome (a common syndrome that includes insulin resistance) are also reviewed separately. (See  <a class="medical medical_review" href="/d/html/1784.html" rel="external">"Metabolic syndrome (insulin resistance syndrome or syndrome X)"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITION AND CAUSES</span><span class="headingEndMark"> — </span>Insulin resistance may be defined as a subnormal glucose response to endogenous and/or exogenous insulin. It most commonly occurs in association with obesity but may result from multiple other underlying causes  (<a class="graphic graphic_table graphicRef75383" href="/d/graphic/75383.html" rel="external">table 1</a>) [<a href="#rid3">3</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Obesity associated</p><p class="bulletIndent1"><span class="glyph">●</span>Stress induced (due to excess counterregulatory hormones cortisol, growth hormone, catecholamines, glucagon)</p><p class="bulletIndent1"><span class="glyph">●</span>Medications (eg, glucocorticoids, human immunodeficiency virus [HIV] antiretrovirals, oral contraceptives)</p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy (placental lactogen)</p><p class="bulletIndent1"><span class="glyph">●</span>Lipodystrophy associated</p><p class="bulletIndent1"><span class="glyph">●</span>Insulin antibodies</p><p class="bulletIndent1"><span class="glyph">●</span>Genetic defects in insulin-signaling pathways – Type A insulin resistance</p><p class="bulletIndent1"><span class="glyph">●</span>Blocking autoantibodies against the insulin receptor – Type B insulin resistance</p><p></p><p class="headingAnchor" id="H6"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Insulin resistance can present in a variety of ways depending on the underlying etiology and severity. Consequences of obesity-related insulin resistance include:</p><p class="bulletIndent1"><span class="glyph">●</span>Impaired glucose tolerance, impaired fasting glucose, type 2 diabetes mellitus, increased insulin requirements in type 1 diabetes</p><p class="bulletIndent1"><span class="glyph">●</span>Coronary artery disease</p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic syndrome</p><p class="bulletIndent1"><span class="glyph">●</span>Polycystic ovary syndrome (PCOS)</p><p class="bulletIndent1"><span class="glyph">●</span>Nonalcoholic fatty liver disease</p><p class="bulletIndent1"><span class="glyph">●</span>Certain obesity-related malignancies (eg, endometrial cancer)</p><p></p><p>The genetic syndromes of severe insulin resistance are a clinically diverse group. Although obesity-related and other forms of insulin resistance share similar clinical features, patients with the genetic syndromes typically have extreme insulin resistance and therefore more severe phenotypes  (<a class="graphic graphic_table graphicRef73294" href="/d/graphic/73294.html" rel="external">table 2</a>).</p><p>In most cases, the precise basis for the link between insulin resistance and the clinical findings is not yet identified. It is likely that high serum insulin concentrations generated largely in response to the rising glucose levels overstimulate specific insulin-responsive pathways that are less impaired than those affecting glucose transport. This may occur from pathway-specific differences in insulin sensitivity or via activation of insulin-like growth factor-1 (IGF-1) receptors or hybrid receptors formed by covalent linkage of subunits of the homologous receptors for insulin and IGF-1, as is hypothesized to occur in PCOS  (<a class="graphic graphic_figure graphicRef61896" href="/d/graphic/61896.html" rel="external">figure 1</a>).</p><p class="headingAnchor" id="H1840582776"><span class="h2">Distribution of adipose tissue</span><span class="headingEndMark"> — </span>In obesity-related insulin resistance, central or abdominal obesity as well as ectopic fat deposition (eg, in muscle and liver) are common. There is a relative deficiency of adipose tissue storage space in the usual fat depot sites, resulting in fat deposited in muscle and liver and an abnormal distribution of adipose tissue that underlies the development of insulin resistance, although the precise mechanism is not fully understood. (See  <a class="medical medical_review" href="/d/html/1810.html" rel="external">"Pathogenesis of type 2 diabetes mellitus", section on 'Role of diet, obesity, and inflammation'</a>.)</p><p>In patients with type A (insulin receptor mutations) and type B (anti-insulin receptor antibodies) insulin resistance, the amount and distribution of adipose tissue may be normal since, in these cases, the underlying mechanism involves dysfunction of the insulin receptors per se.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abdominal obesity</strong> – An increasing number of individuals in Western societies have general obesity and/or abdominal obesity. High serum free fatty acid concentrations in the circulation and/or excess fat deposition in muscle or liver (derived from enlarged adipose cells, the storage capacity of which has been exceeded) have been implicated in the pathogenesis of obesity-related metabolic disorders, including insulin resistance [<a href="#rid4">4-6</a>]. Macrophages are attracted to the dystopic fat deposition areas to phagocytose adipocytes, and this initiates a chronic, low-grade inflammatory state. (See  <a class="medical medical_review" href="/d/html/1810.html" rel="external">"Pathogenesis of type 2 diabetes mellitus", section on 'Role of diet, obesity, and inflammation'</a>.)</p><p></p><p class="bulletIndent1">Increased release of adipocytokines, such as tumor necrosis factor (TNF)-alpha, or decreased production of protective adipocytokines, such as adiponectin [<a href="#rid7">7</a>], are thought to mediate the effects of obesity in the pathogenesis of insulin resistance and, subsequently, the metabolic syndrome and type 2 diabetes. Adiponectin levels are decreased with intraabdominal fat accumulation and increased with healthy dietary patterns and exercise [<a href="#rid8">8-10</a>]. Low adiponectin levels are associated with high circulating levels of insulin, IGF-1, and proinflammatory cytokines, all of which lead to obesity and insulin resistance-related comorbidities in genetically predisposed individuals. (See  <a class="medical medical_review" href="/d/html/1810.html" rel="external">"Pathogenesis of type 2 diabetes mellitus", section on 'Role of diet, obesity, and inflammation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lipoatrophy</strong> – The lipodystrophy syndromes are a clinically diverse group of disorders characterized by either complete or partial lack of adipose tissue (lipoatrophy), sometimes in conjunction with apparent accumulation of fat in other regions of the body where fat should not exist (dystopic fat deposition in muscle and liver). The patients often have severe tissue resistance to insulin and may have some of the other clinical features of insulin resistance, such as acanthosis nigricans. The syndromes can be congenital or acquired, and atrophy of adipose tissue can be total or partial [<a href="#rid4">4</a>]. The results of studies of the pathogenesis of insulin resistance in the context of lipoatrophy have varied regarding the presence or absence of defects at the level of insulin receptor expression, function, and signaling, as well as in genes involved in adipogenesis. Adiponectin and leptin levels are low in some patients with lipoatrophy [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/1788.html" rel="external">"Lipodystrophic syndromes", section on 'Lipodystrophies and insulin resistance'</a>.)</p><p></p><p class="bulletIndent1">A syndrome of acquired lipodystrophy is associated with antiretroviral therapy (ART), including protease-inhibitors in patients with human immunodeficiency virus (HIV) infection. These patients have insulin resistance and develop lipoatrophy and/or dystopic fat deposition, as well as metabolic abnormalities. (See  <a class="medical medical_review" href="/d/html/3733.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy"</a>.)</p><p></p><p class="headingAnchor" id="H7"><span class="h2">Abnormal glucose metabolism</span><span class="headingEndMark"> — </span>The spectrum of abnormalities in glucose homeostasis is variable and depends upon the underlying etiology and severity and on the ability of beta cells to respond to insulin resistance with increased insulin secretion, which differs widely among patients.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obesity related</strong> – Obesity, particularly abdominal obesity, is associated with resistance to the effects of insulin on peripheral glucose and fatty acid utilization, often leading to type 2 diabetes mellitus. Many patients with obesity-related insulin resistance initially have normal or only slightly high blood glucose concentrations. In many cases, however, pancreatic beta cells eventually fail to compensate for insulin resistance and hyperglycemia develops. Patients may have impaired fasting glucose or impaired glucose tolerance prior to developing overt type 2 diabetes. Some patients require large doses of insulin to control hyperglycemia. (See  <a class="medical medical_review" href="/d/html/1810.html" rel="external">"Pathogenesis of type 2 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic syndromes of severe insulin resistance</strong> – In patients with genetic syndromes of severe insulin resistance, hyperglycemia despite large doses of insulin is the classical presentation since very high insulin levels may not be effective given the dysfunctional insulin receptor. However, certain patients with extreme resistance to insulin may not present with overt hyperglycemia, particularly during the early phases of developing insulin resistance since normal glucose levels are maintained at the expense of rising insulin levels. Not infrequently, patients may initially have only postprandial hyperglycemia (or abnormal oral glucose tolerance testing) well before they develop sustained hyperglycemia.</p><p></p><p class="bulletIndent1">Other patients may develop postprandial hypoglycemia due to rising insulin levels well before they develop sustained hyperglycemia. It has been hypothesized that this results from impairment of hepatic insulin clearance in patients with insulin receptor defects or secondarily as a consequence of hepatic steatosis. In addition, a small percentage of patients may initially present with hypoglycemia due to developing activating autoantibodies to the insulin receptor [<a href="#rid3">3,11-13</a>].</p><p></p><p>Abnormalities in glucose metabolism related to glucocorticoid therapy and in response to infection or critical illness (stress hyperglycemia) are reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/1812.html" rel="external">"Clinical presentation, diagnosis, and initial evaluation of diabetes mellitus in adults", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/d/html/1600.html" rel="external">"Glycemic control in critically ill adult and pediatric patients"</a> and  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids", section on 'Metabolic and endocrine effects'</a>.)</p><p class="headingAnchor" id="H1296405479"><span class="h2">Metabolic syndrome</span><span class="headingEndMark"> — </span>In patients with obesity, particularly abdominal obesity, insulin resistance, the associated hyperinsulinemia and hyperglycemia, and adipocyte cytokines (adipokines) may lead to vascular endothelial dysfunction, an abnormal lipid profile, hypertension, and vascular inflammation, all of which promote the development of atherosclerotic cardiovascular disease (CVD). The metabolic syndrome is defined as the co-occurrence of metabolic risk factors for both type 2 diabetes and CVD (abdominal obesity, hyperglycemia, dyslipidemia, and hypertension). There are several definitions for the metabolic syndrome. This topic is reviewed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1784.html" rel="external">"Metabolic syndrome (insulin resistance syndrome or syndrome X)"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Acanthosis nigricans</span><span class="headingEndMark"> — </span>Acanthosis nigricans and skin tags are commonly associated with insulin resistance, regardless of its cause. Acanthosis nigricans is a skin lesion characterized by brown, velvety, hyperkeratotic plaques. The lesions are usually found on the back of the neck, the axilla  (<a class="graphic graphic_picture graphicRef53776" href="/d/graphic/53776.html" rel="external">picture 1</a>), the groin, and over the elbows, but they may cover the entire surface of the skin, sparing only the palms and soles. The lesions may be papillomatous. Histologic hallmarks are hyperkeratosis, epidermal papillomatosis, and increased numbers of melanocytes. (See  <a class="medical medical_review" href="/d/html/13754.html" rel="external">"Acanthosis nigricans"</a>.)</p><p>The common denominator in all cases of acanthosis nigricans, with the possible exception of tumor-induced lesions, is insulin resistance and, more specifically, elevated insulin and IGF-1 levels due to insulin resistance [<a href="#rid14">14</a>]. It may vary in severity and may be inherited or acquired.</p><p class="headingAnchor" id="H9"><span class="h2">Hyperandrogenism and reproductive abnormalities</span><span class="headingEndMark"> — </span>Women with insulin resistance commonly present with reproductive abnormalities, whereas men with insulin resistance are not known to have disorders of the reproductive system.</p><p>As an example, most women with severe tissue resistance to insulin, regardless of cause, have marked hyperandrogenism. This association has been described in women with the type B syndrome (caused by insulin-receptor autoantibodies) [<a href="#rid15">15,16</a>] or the type A syndrome (caused by genetic defects in the insulin-signaling system, such as mutations in the insulin receptor gene) [<a href="#rid17">17,18</a>]. Affected women can present with overt virilization or hirsutism, amenorrhea, and infertility. The ovaries show a polycystic pattern on ultrasound.</p><p>Most women with ovarian hyperandrogenism have tissue resistance to insulin that is identified by fasting hyperinsulinemia or subnormal insulin-mediated glucose uptake (from euglycemic clamp studies) [<a href="#rid19">19</a>]. The basis for the association between insulin resistance and ovarian hyperandrogenism is not entirely clear [<a href="#rid20">20,21</a>]. Studies in cultured skin fibroblasts suggest that approximately 50 percent of them have a defect in phosphorylation of the insulin receptor [<a href="#rid20">20</a>]. Insulin receptors, and the closely related receptors for IGF-1, are present on ovarian cells, and stimulation of these receptors in the presence of adequate luteinizing hormone (LH) increases androgen production  (<a class="graphic graphic_figure graphicRef61896" href="/d/graphic/61896.html" rel="external">figure 1</a>) [<a href="#rid22">22</a>]. Excess androgens in turn produce insulin resistance by direct effects on insulin action in skeletal muscle and adipose tissue, altering adipokine secretion, and increasing visceral adiposity [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/d/html/7436.html" rel="external">"Clinical manifestations of polycystic ovary syndrome in adults"</a> and  <a class="medical medical_review" href="/d/html/7430.html" rel="external">"Epidemiology, phenotype, and genetics of the polycystic ovary syndrome in adults"</a> and  <a class="medical medical_review" href="/d/html/7411.html" rel="external">"Metformin for treatment of the polycystic ovary syndrome", section on 'Potential uses'</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Linear and acral growth</span><span class="headingEndMark"> — </span>Linear growth is normal in most patients with insulin resistance. There are, however, two pediatric disorders with severe insulin resistance, Leprechaunism, which almost universally results in a fatal outcome soon after birth, and the Rabson-Mendenhall syndrome, in which growth is impaired [<a href="#rid3">3,23,24</a>]. These syndromes are due to mutations in the insulin receptor gene (<em>INSR</em>), which result in complete or nearly complete absence of insulin receptor function [<a href="#rid3">3</a>]. They are associated with markedly delayed linear growth and failure to thrive due to the cross reactivity of insulin and IGF-1 with each other's receptors as well as the existence of hybrid insulin-IGF-1 receptors that mediate growth.</p><p>Pseudoacromegaly, in contrast, is a syndrome in which severe insulin resistance is associated with accelerated linear growth [<a href="#rid25">25</a>]. In these patients, hyperinsulinemia probably promotes linear growth by activating skeletal IGF-1 receptors.</p><p class="headingAnchor" id="H3260076063"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H3108829405"><span class="h2">Obesity-related insulin resistance</span><span class="headingEndMark"> — </span>The diagnosis of insulin resistance in most patients is based upon clinical findings (eg, metabolic syndrome traits):</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperglycemia</p><p class="bulletIndent1"><span class="glyph">●</span>Dyslipidemia</p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal obesity</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension</p><p></p><p>In a clinical setting, it would be useful to quantify insulin resistance in patients with obesity as they are at highest risk for the development of type 2 diabetes mellitus and its complications [<a href="#rid26">26</a>], cardiovascular disease (CVD), and certain malignancies associated with obesity and insulin resistance (eg, colon, breast, and endometrial cancers). However, there is currently no acceptable test for measuring insulin resistance in a clinical setting.</p><p>In nondiabetic, normotensive overweight individuals, the following tests are sometimes used, but none have been fully validated in the clinical setting.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Triglycerides, HDL, fasting insulin</strong> – Serum triglyceride concentration, the ratio of triglyceride to high-density lipoprotein (HDL) cholesterol concentrations, and fasting insulin concentration are useful markers for identifying those who may be insulin resistant (as measured by an insulin suppression test). Optimal cutoff points were identified as 130 mg/dL (1.47 mmol/L), 3.0 (1.8 SI units), and 15.7 microU/mL (109 pmol/L) for triglycerides, triglyceride-to-HDL ratio, and insulin, respectively [<a href="#rid27">27</a>]. Sensitivity and specificity for these thresholds were 67, 64, and 57 percent, respectively, and 71, 68, and 85 percent, respectively, which are not in the range that would make these tests clinically recommended.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Insulin-to-glucose ratio</strong> – Some clinicians use a fasting plasma insulin-to-glucose ratio to assess the degree of insulin resistance. This is of value at early stages of insulin resistance when pancreatic beta cells continue to secrete appropriate amounts of insulin. In this setting, higher insulin-to-glucose ratios indicate higher levels of insulin resistance. As the pancreatic beta cells begin to fail, however, insulin levels decline, and the ratio is less useful. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SHBG</strong> – Infrequently, serum sex hormone-binding globulin (SHBG) is used as a marker for insulin resistance. A low serum SHBG concentration has been associated with insulin resistance and an increased incidence of type 2 diabetes [<a href="#rid28">28</a>].</p><p></p><p>In the research setting, several techniques are used to measure insulin resistance:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Euglycemic clamp/IVGTT/ITT</strong> – The euglycemic insulin clamp technique has been considered to be the gold standard  (<a class="graphic graphic_figure graphicRef69265" href="/d/graphic/69265.html" rel="external">figure 2</a>), and an intravenous glucose tolerance test (IVGTT) and/or insulin tolerance test (ITT)/insulin suppression test are most frequently used because they are easier to perform [<a href="#rid29">29,30</a>]. However, these techniques are impractical for routine clinical use.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HOMA</strong> – In large, population-based epidemiology studies, simple ratios derived from fasting insulin and glucose (eg, glucose-to-insulin ratios, homeostasis model assessment of insulin resistance [HOMA-IR or HOMA]) have been extensively employed. There are limitations to their use, including changes in beta cell function over time, lack of a standardized universal insulin assay, and lack of data demonstrating that markers of insulin resistance predict response to treatment. In addition, there are rare cases of mutations in the insulin gene resulting in the production of insulin that has subnormal bioactivity but normal immunoactivity. These insulins circulate at high concentrations, simulating insulin resistance, but the response to exogenous insulin is normal [<a href="#rid31">31</a>]. Therefore, although indexes such as HOMA and quantitative insulin sensitivity check index (QUICKI) or other tests of insulin resistance have been proposed and cutpoints identified [<a href="#rid32">32,33</a>], none are recommended for routine assessment of insulin resistance in the clinical setting.</p><p></p><p class="headingAnchor" id="H650637065"><span class="h2">Severe phenotype of insulin resistance</span><span class="headingEndMark"> — </span>In patients with severe phenotypes suggesting an inherited state of target cell resistance (eg, Leprechaunism, which is extremely rare since most patients die in utero or soon after birth, or Rabson-Mendenhall syndrome) or with lipodystrophy phenotypes, fasting serum insulin should be measured. The finding of marked hyperinsulinemia (with normal or high blood glucose) should prompt further studies to evaluate for the presence of insulin receptor mutations, circulating anti-insulin receptor antibodies, or other disorders  (<a class="graphic graphic_table graphicRef75383" href="/d/graphic/75383.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/1788.html" rel="external">"Lipodystrophic syndromes"</a>.)</p><p class="headingAnchor" id="H2101924"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Insulin resistance is a state in which a given concentration of insulin is associated with a subnormal glucose response. Important long-term consequences of insulin resistance include the development of type 2 diabetes, cardiovascular disease (CVD), and certain malignancies associated with obesity and insulin resistance. (See <a class="local">'Definition and causes'</a> above and <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Insulin resistance is associated with a variety of clinical presentations based on its severity  (<a class="graphic graphic_table graphicRef73294" href="/d/graphic/73294.html" rel="external">table 2</a>). Some of these features include acanthosis nigricans, ovarian hyperandrogenism (polycystic ovary syndrome [PCOS]), lipodystrophy, accelerated or impaired linear growth, autoimmunity, and muscle cramps. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with obesity, the diagnosis of insulin resistance is based upon clinical findings (eg, hyperglycemia, dyslipidemia, abdominal obesity, hypertension). There currently is no validated test for measuring insulin resistance in a clinical setting. As a result, we do not routinely measure insulin resistance in patients without severe phenotypes. (See <a class="local">'Diagnosis'</a> above and  <a class="medical medical_review" href="/d/html/1784.html" rel="external">"Metabolic syndrome (insulin resistance syndrome or syndrome X)", section on 'Definition'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In research settings, the euglycemic insulin clamp technique has been considered to be the gold standard, although easier to perform intravenous glucose tolerance testing (IVGTT) and/or insulin tolerance test (ITT)/insulin suppression testing are most frequently performed to identify patients who are insulin resistant. However, these techniques are impractical for routine clinical use. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with severe phenotypes suggesting an inherited state of target cell resistance (eg, Leprechaunism, Rabson-Mendenhall syndrome) or with lipodystrophy phenotypes, fasting insulin should be measured. The finding of marked hyperinsulinemia should prompt further studies to evaluate the presence of insulin receptor mutations, circulating anti-insulin receptor antibodies, and other disorders  (<a class="graphic graphic_table graphicRef75383" href="/d/graphic/75383.html" rel="external">table 1</a>). (See <a class="local">'Diagnosis'</a> above and  <a class="medical medical_review" href="/d/html/1788.html" rel="external">"Lipodystrophic syndromes"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Moller DE, Flier JS. Insulin resistance--mechanisms, syndromes, and implications. N Engl J Med 1991; 325:938.</a></li><li><a class="nounderline abstract_t">Kahn CR, Rosenthal AS. Immunologic reactions to insulin: insulin allergy, insulin resistance, and the autoimmune insulin syndrome. Diabetes Care 1979; 2:283.</a></li><li><a class="nounderline abstract_t">Semple RK, Savage DB, Cochran EK, et al. Genetic syndromes of severe insulin resistance. Endocr Rev 2011; 32:498.</a></li><li><a class="nounderline abstract_t">Fiorenza CG, Chou SH, Mantzoros CS. Lipodystrophy: pathophysiology and advances in treatment. Nat Rev Endocrinol 2011; 7:137.</a></li><li><a class="nounderline abstract_t">Björntorp P. "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990; 10:493.</a></li><li><a class="nounderline abstract_t">Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259:87.</a></li><li><a class="nounderline abstract_t">Ziemke F, Mantzoros CS. Adiponectin in insulin resistance: lessons from translational research. Am J Clin Nutr 2010; 91:258S.</a></li><li><a class="nounderline abstract_t">Gavrila A, Chan JL, Yiannakouris N, et al. Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J Clin Endocrinol Metab 2003; 88:4823.</a></li><li><a class="nounderline abstract_t">Fargnoli JL, Fung TT, Olenczuk DM, et al. Adherence to healthy eating patterns is associated with higher circulating total and high-molecular-weight adiponectin and lower resistin concentrations in women from the Nurses' Health Study. Am J Clin Nutr 2008; 88:1213.</a></li><li><a class="nounderline abstract_t">Blüher M, Williams CJ, Klöting N, et al. Gene expression of adiponectin receptors in human visceral and subcutaneous adipose tissue is related to insulin resistance and metabolic parameters and is altered in response to physical training. Diabetes Care 2007; 30:3110.</a></li><li><a class="nounderline abstract_t">Taylor SI, Grunberger G, Marcus-Samuels B, et al. Hypoglycemia associated with antibodies to the insulin receptor. N Engl J Med 1982; 307:1422.</a></li><li><a class="nounderline abstract_t">Viswanathan L, Sirisena I. Immunosuppressive Therapy in Treatment of Refractory Hypoglycemia in Type B Insulin Resistance: A Case Report. J Endocr Soc 2017; 1:1435.</a></li><li><a class="nounderline abstract_t">Bourron O, Caron-Debarle M, Hie M, et al. Type B Insulin-resistance syndrome: a cause of reversible autoimmune hypoglycaemia. Lancet 2014; 384:1548.</a></li><li><a class="nounderline abstract_t">Rogers DL. Acanthosis nigricans. Semin Dermatol 1991; 10:160.</a></li><li><a class="nounderline abstract_t">Taylor SI, Dons RF, Hernandez E, et al. Insulin resistance associated with androgen excess in women with autoantibodies to the insulin receptor. Ann Intern Med 1982; 97:851.</a></li><li><a class="nounderline abstract_t">Brown RJ, Joseph J, Cochran E, et al. Type B Insulin Resistance Masquerading as Ovarian Hyperthecosis. J Clin Endocrinol Metab 2017; 102:1789.</a></li><li><a class="nounderline abstract_t">Taylor SI, Cama A, Accili D, et al. Mutations in the insulin receptor gene. Endocr Rev 1992; 13:566.</a></li><li><a class="nounderline abstract_t">Moller DE, Cohen O, Yamaguchi Y, et al. Prevalence of mutations in the insulin receptor gene in subjects with features of the type A syndrome of insulin resistance. Diabetes 1994; 43:247.</a></li><li><a class="nounderline abstract_t">Dunaif A, Segal KR, Shelley DR, et al. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992; 41:1257.</a></li><li><a class="nounderline abstract_t">Dunaif A, Xia J, Book CB, et al. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995; 96:801.</a></li><li><a class="nounderline abstract_t">Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 2012; 33:981.</a></li><li><a class="nounderline abstract_t">Barbieri RL, Smith S, Ryan KJ. The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism. Fertil Steril 1988; 50:197.</a></li><li><a class="nounderline abstract_t">Elders MJ, Schedewie HK, Olefsky J, et al. Endocrine-metabolic relationships in patients with leprechaunism. J Natl Med Assoc 1982; 74:1195.</a></li><li><a class="nounderline abstract_t">RABSON SM, MENDENHALL EN. Familial hypertrophy of pineal body, hyperplasia of adrenal cortex and diabetes mellitus; report of 3 cases. Am J Clin Pathol 1956; 26:283.</a></li><li><a class="nounderline abstract_t">Flier JS, Moller DE, Moses AC, et al. Insulin-mediated pseudoacromegaly: clinical and biochemical characterization of a syndrome of selective insulin resistance. J Clin Endocrinol Metab 1993; 76:1533.</a></li><li><a class="nounderline abstract_t">Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 2018; 6:361.</a></li><li><a class="nounderline abstract_t">McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003; 139:802.</a></li><li><a class="nounderline abstract_t">Wallace IR, McKinley MC, Bell PM, Hunter SJ. Sex hormone binding globulin and insulin resistance. Clin Endocrinol (Oxf) 2013; 78:321.</a></li><li><a class="nounderline abstract_t">Buchanan TA, Watanabe RM, Xiang AH. Limitations in surrogate measures of insulin resistance. J Clin Endocrinol Metab 2010; 95:4874.</a></li><li><a class="nounderline abstract_t">Tritos NA, Mantzoros CS. Clinical review 97: Syndromes of severe insulin resistance. J Clin Endocrinol Metab 1998; 83:3025.</a></li><li><a class="nounderline abstract_t">Steiner DF, Tager HS, Chan SJ, et al. Lessons learned from molecular biology of insulin-gene mutations. Diabetes Care 1990; 13:600.</a></li><li><a class="nounderline abstract_t">Ascaso JF, Pardo S, Real JT, et al. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 2003; 26:3320.</a></li><li><a class="nounderline abstract_t">Cobb J, Gall W, Adam KP, et al. A novel fasting blood test for insulin resistance and prediabetes. J Diabetes Sci Technol 2013; 7:100.</a></li></ol></div><div id="topicVersionRevision">Topic 1762 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1881419" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Insulin resistance--mechanisms, syndromes, and implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/510122" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Immunologic reactions to insulin: insulin allergy, insulin resistance, and the autoimmune insulin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21536711" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Genetic syndromes of severe insulin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21079616" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Lipodystrophy: pathophysiology and advances in treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2196039" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7678183" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19906806" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Adiponectin in insulin resistance: lessons from translational research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557461" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18996855" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Adherence to healthy eating patterns is associated with higher circulating total and high-molecular-weight adiponectin and lower resistin concentrations in women from the Nurses' Health Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17878241" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Gene expression of adiponectin receptors in human visceral and subcutaneous adipose tissue is related to insulin resistance and metabolic parameters and is altered in response to physical training.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7133096" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Hypoglycemia associated with antibodies to the insulin receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29264467" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Immunosuppressive Therapy in Treatment of Refractory Hypoglycemia in Type B Insulin Resistance: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25390580" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Type B Insulin-resistance syndrome: a cause of reversible autoimmune hypoglycaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1931564" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Acanthosis nigricans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7149493" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Insulin resistance associated with androgen excess in women with autoantibodies to the insulin receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27911591" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Type B Insulin Resistance Masquerading as Ovarian Hyperthecosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1330507" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Mutations in the insulin receptor gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8288049" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prevalence of mutations in the insulin receptor gene in subjects with features of the type A syndrome of insulin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1397698" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7635975" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23065822" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3294042" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7154104" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Endocrine-metabolic relationships in patients with leprechaunism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13302174" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Familial hypertrophy of pineal body, hyperplasia of adrenal cortex and diabetes mellitus; report of 3 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8388881" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Insulin-mediated pseudoacromegaly: clinical and biochemical characterization of a syndrome of selective insulin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29503172" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14623617" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Use of metabolic markers to identify overweight individuals who are insulin resistant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23121642" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Sex hormone binding globulin and insulin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21051585" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Limitations in surrogate measures of insulin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9745395" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical review 97: Syndromes of severe insulin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2192846" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Lessons learned from molecular biology of insulin-gene mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14633821" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23439165" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A novel fasting blood test for insulin resistance and prediabetes.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
